Avoparcin chemical review

Discontinued

Avoparcin is a gram-positive glycopeptide antibiotic used in livestock feed for growth promotion in broiler chickens, growing pigs, calves and beef cattle. Avoparcin is also used as an aid in the prevention of necrotic enteritis in poultry.

Work plan

Work plan

Click on the tabs for more information about the status of each phase in the review process. For more information about how each phase is conducted, please read about the reconsideration process.

Chemicals

  • Avoparcin
1. Nomination

1. Nomination

Phase status

Completed

Avoparcin is a gram-positive glycopeptide antibiotic used in livestock feed for growth promotion in broiler chickens, growing pigs, calves and beef cattle. Avoparcin is also used as an aid in the prevention of necrotic enteritis in poultry.

There are currently no registered products containing avoparcin in Australia.

2. Prioritisation

2. Prioritisation

Phase status

Completed
3. Scoping and work plan

3. Scoping and work plan

Phase status

Completed
4. Notice of reconsideration

4. Notice of reconsideration

Phase status

Completed
5. Assessment

5. Assessment

Phase status

Not required

The registrants did not renew the registration of their products after 30 June 2000 and voluntarily withdrew avoparcin from the market.

The APVMA completed the assessment of the residues data but did not continue with the review, as it was not likely to be completed before the withdrawal of avoparcin products from the market. The conclusions of the residues assessment are in the APVMA’s Avoparcin status document.

The APVMA will reactivate the review of avoparcin if the registrations of any products containing avoparcin are renewed. Any applicant interested in registering products containing avoparcin must provide data in accordance with the APVMA’s Manual of requirements and guidelines. Applicants must also provide a risk analysis of microbial resistance safety as outlined in the Guidelines for registering vet chemicals, Part 10, Special data requirements.

6. Proposed regulatory decision

6. Proposed regulatory decision

Phase status

Not required
7. Consultation

7. Consultation

Phase status

Not required
8. Final regulatory decision

8. Final regulatory decision

Phase status

Not required
9. Implementation

9. Implementation

Phase status

Not required

In 2006, the APVMA withdrew the maximum residue limit (MRL) for avoparcin.

Publication archive

Publication Archive

Type  Title  Publication date
Gazette Deletion of MRL  3 Octobeer 2006
Gazette  List of non-renewed registrations 5 September 2000
Report Avoparcin status document January 2001

 

Was this page helpful?

Your feedback will be submitted to the APVMA anonymously. If you require a response, please contact us.

CAPTCHA